New drug for neuroblastoma shows promise in phase I study

Researchers have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. The clinical trial showed minimal side effects with long-term survival of three patients. This is the first clinical study of an oral dosing form of DFMO in any pediatric population.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1HGioVl